GSK Plc raised its profit and sales forecasts for the year, aided by its HIV and immunology medicines, in Emma Walmsley’s ...

GSK lifted profit expectations for the year after the pharma group's sales were boosted by bumper demand for HIV and cancer ...

GSK raised its full-year guidance on Wednesday, after delivering stronger-than-expected third-quarter results, driven by ...

Cash generated from operations totaled £2.5 billion, with free cash flow of £1.2 billion. GSK declared a dividend of 16 pence ...

GSK has received approval from the US Food and Drug Administration (FDA) for Blenrep (belantamab mafodotin-blmf) in ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

GSK’s Blenrep receives US FDA approval to treat relapsed/refractory multiple myeloma: London, UK Saturday, October 25, 2025, 11:00 Hrs [IST] GSK plc announced the US Food and Dr ...

The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

The FDA has approved belantamabmafodotin (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd)for the ...

GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...

The US Food and Drug Administration (FDA) has approved UK pharma major GSK’s Blenrep belantamab mafodotin-blmf) in ...

CURE spoke with Dr. Surbhi Sidana about the recently approved antibody-drug conjugate Blenrep for multiple myeloma.